Skip to main content
News

News

Predicting Pharmacokinetic versus Pharmacodynamic Aspirin Resistance in Patients

Posted on: 02/24/2017

Abstract TP412: Predicting Pharmacokinetic versus Pharmacodynamic Aspirin Resistance in Patients
Erica S Westphal, Michelle M Rainka, Michelle Amsler, Traci Aladeen, Caitlin Snyder, Vernice Bates and Fran M Gengo
Stroke. 2017;48:ATP412, originally published February 21, 2017

20%-40% of patients being treated with aspirin for secondary prophylaxis of stroke or myocardial infarction may derive no antiplatelet effects. Early identification of patients as pharmacokinetically or pharmacodynamically resistant to aspirin has the potential to become an invaluable clinical tool, reducing delays to optimal treatment, cardiovascular events, and healthcare costs. This study tested the capability of an assay that was previously developed in healthy volunteers, to differentiate between these two types of resistance in patients. Continue Reading

Back to Article List